Neuroprotective Effects of the Glucagon-Like Peptide-1 Analog Exenatide After Out-of-Hospital Cardiac Arrest: A Randomized Controlled Trial.

Wiberg S, Hassager C, Schmidt H, Thomsen JH, Frydland M, Lindholm MG, Høfsten DE, Engstrøm T, Køber L, Møller JE, Kjaergaard J

Circulation12 Nov 2016Cited by 51 (Europe PMC)

PMID27838646DOI10.1161/circulationaha.116.024088PepBankPUB-27838646

Publisher page PubMedAsk about this study

Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In resuscitated cardiac arrest patients, exenatide did not significantly change neuron-specific enolase area under the curve compared with placebo.
In plain wordsIn cardiac arrest patients, exenatide did not significantly change the brain injury marker curve compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeNeuron-specific enolase area under curve
Study
n = 120
Comparator
Placebo
Analysis
Primary
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
17.4 μg · infusion · 6 hours and 15 minutesAs given in this study (human).
Source sentences
Summary
However, there were no significant differences in the area under the neuron-specific enolase curve, or a composite end point of death and poor neurological function between groups.
2 context sentences(design, population, supporting numbers)
Summary · context
We randomly assigned 120 consecutive comatose patients resuscitated from OHCA in a double-blind, 2-center trial.
Summary · context
They were administered 17.4 μg exenatide (Byetta) or placebo over a 6-hour and 15-minute infusion, in addition to standardized intensive care including targeted temperature management.
Report a problemFND-2783864603
02HumanRandomized controlled trialEfficacy outcome
In resuscitated cardiac arrest patients, exenatide did not significantly change the composite of death and poor neurological function compared with placebo.
In plain wordsIn cardiac arrest patients, exenatide did not significantly change the combined outcome of death and poor neurological function compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeComposite death and poor neurological function
Study
n = 120
Comparator
Placebo
Analysis
Secondary
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
17.4 μg · infusion · 6 hours and 15 minutesAs given in this study (human).
Source sentences
Summary
However, there were no significant differences in the area under the neuron-specific enolase curve, or a composite end point of death and poor neurological function between groups.
2 context sentences(design, population, supporting numbers)
Summary · context
We randomly assigned 120 consecutive comatose patients resuscitated from OHCA in a double-blind, 2-center trial.
Summary · context
They were administered 17.4 μg exenatide (Byetta) or placebo over a 6-hour and 15-minute infusion, in addition to standardized intensive care including targeted temperature management.
Report a problemFND-2783864604
03HumanRandomized controlled trialEfficacy outcome
In resuscitated cardiac arrest patients, exenatide lowered median blood glucose at 8 hours compared with placebo.
In plain wordsIn cardiac arrest patients, exenatide lowered blood sugar at 8 hours compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBlood glucose eight hours after admission
Study
n = 120
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
17.4 μg · infusion · 6 hours and 15 minutesAs given in this study (human).
Measurements
Median blood glucose
5.8 mmol/L
exenatide
Median blood glucose
7.3 mmol/L
placebo
Source sentences
Summary
The median blood glucose 8 hours after admission in patients receiving exenatide was lower than that in patients receiving placebo (5.8 [5.2-6.7] mmol/L versus 7.3 [6.2-8.7] mmol/L, P<0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
We randomly assigned 120 consecutive comatose patients resuscitated from OHCA in a double-blind, 2-center trial.
Summary · context
They were administered 17.4 μg exenatide (Byetta) or placebo over a 6-hour and 15-minute infusion, in addition to standardized intensive care including targeted temperature management.
Report a problemFND-2783864602
04HumanRandomized controlled trialSafety outcome
In resuscitated cardiac arrest patients, adverse events were rare and did not differ significantly between exenatide and placebo.
In plain wordsIn cardiac arrest patients, adverse events were rare and did not differ significantly between exenatide and placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeAdverse events
Study
n = 120
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
17.4 μg · infusion · 6 hours and 15 minutesAs given in this study (human).
Source sentences
Summary
Adverse events were rare with no significant difference between groups.
2 context sentences(design, population, supporting numbers)
Summary · context
We randomly assigned 120 consecutive comatose patients resuscitated from OHCA in a double-blind, 2-center trial.
Summary · context
They were administered 17.4 μg exenatide (Byetta) or placebo over a 6-hour and 15-minute infusion, in addition to standardized intensive care including targeted temperature management.
Report a problemFND-2783864605

Studies that did not test the peptide alone1

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

05HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialOther
In resuscitated cardiac arrest patients assigned exenatide or placebo, study drug initiation occurred within 240 minutes in 96%.
In plain wordsIn cardiac arrest patients assigned exenatide or placebo, 96% started the study drug within 240 minutes.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableTimely study drug initiation
Study
n = 120
Analysis
Primary
Outcome group
Overall treatment effect · Whole body
Measurements
Timely initiation
96%
study drug, both groups
Source sentences
Summary
The study drug was initiated within 240 minutes of return of spontaneous circulation in 96% patients.
2 context sentences(design, population, supporting numbers)
Summary · context
We randomly assigned 120 consecutive comatose patients resuscitated from OHCA in a double-blind, 2-center trial.
Summary · context
They were administered 17.4 μg exenatide (Byetta) or placebo over a 6-hour and 15-minute infusion, in addition to standardized intensive care including targeted temperature management.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2783864601

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableNCT02442791

GLP-1 Analogs for Neuroprotection After Cardiac Arrest

Jesper Kjaergaardn = 120Jun 2014 to Jun 2016

Cardiac Arrest · Coma

Trial page ClinicalTrials.govUpdated 28 Sept 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.